Idorsia Ltd. has released its financial results for the first half of 2025, reporting a significant increase in net revenue to CHF 130 million, compared to CHF 26 million in the same period of 2024. This growth was driven by QUVIVIQ product sales, which contributed CHF 56 million, product sales to partners totaling CHF 2 million, and contract revenues of CHF 73 million. The company also reported a non-GAAP net loss of CHF 25 million, a considerable improvement from the CHF 183 million loss recorded in the first half of 2024. The basic and diluted earnings per share stood at CHF 0.26, a turnaround from a loss per share of CHF 0.44 in the first half of the previous year. Idorsia's US GAAP operating expenses decreased to CHF 75 million from CHF 94 million in the first half of 2024, influenced by a one-off gain of CHF 90 million from the amended Viatris deal. The company anticipates a US-GAAP operating loss of approximately CHF 220 million and expects a US-GAAP EBIT for the partnered business of around CHF 165 million, primarily driven by the Viatris deal. This is projected to result in a US-GAAP loss for the global business of about CHF 55 million, excluding unforeseen events and potential revenue from additional business development activities.